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ABSTRACT
Mortality from severe bacterial sepsis remains high. The pathogenesis involves production of pro and
anti-inﬂammatory cytokines which mediate: neutrophil adhesion to the endothelium, diffuse capillary
leak, disseminated intravascular coagulation, vasodilatation and mitochondrial dysfunction, all of which
culminate in microcirculatory failure. Therapy is multifaceted. As described in ‘the surviving sepsis
guidelines’, many therapeutic interventions, such as early goal-directed resuscitation, low dose
intravenous steroids, strict glucose control, recombinant activated protein C and ventilation according to
ARDS- net criteria are critical to survival. However appropriate empiric antibiotic therapy initiated early
is pivotal. Empiric therapy should be designed with regard to the bacterial epidemiology within the unit
and the aim should be to optimise outcome while yet attempting to reduce the potential for resistance
development. Antibiotic therapy for resistant organisms consists of the carbapenems, including
ertapenem for ESBL’s, cefepime, piperacillin/tazobactam and, on occasion, the Gram-negative
quinolones, ciproﬂoxacin and levoﬂoxacin. Consideration should be given to the possibility of ‘collateral
damage’, where overuse of an antibiotic predisposes to multi-drug resistance. Antibiotics should be
limited, where possible, to those organisms that are pathogens and not colonisers and should be
discontinued if sepsis is not conﬁrmed or there is rapid resolution of clinical indicators of sepsis.
De-escalation strategies should be consistently employed and the duration of therapy should be tailored
to clinical response. Continuation beyond 8 days is generally detrimental in terms of the potential for
superinfection with resistant organisms. Failure of response necessitates, initially, a re-evaluation of
source control and obsessive culturing of likely sites of sepsis prior to random antibiotic changes.
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INTRODUCTION
Severe sepsis results in a series of events that
culminate in organ dysfunction and hypotension
[1]. In the case of Gram-negative sepsis, the
transcription factor, nuclear factor kappa B, is
activated by endotoxin and, in the case of Gram-
positive sepsis, by cell wall products such as
lipotechoic acid and peptide exotoxins. Nuclear
factor kappa B translocates to the nucleus, where it
mediates the production of proinﬂammatory cy-
tokines such as tumour necrosis factor, interleu-
kin-1 and interleukin-6, which mediate adhesion
of polymorphonuclear leukocytes to the endothe-
lium, with consequent capillary leak, coagulation
and vasodilatation. These systemic events and the
organ dysfunction that ensues are associated with
an unacceptably high mortality [2]. This is despite
ongoing progress in the understanding of the
pathogenesis of the condition. The incidence of
severe sepsis has remained similarly high and
actually appears to be increasing [3,4].
Global management strategy
Strategies have been developed to meet this
challenge in the form of the ‘Surviving Sepsis
Guidelines’, which represent an international
consensus on the best available standards for
management of sepsis, regardless of its aetiology
[5]. These guidelines concern the utilisation of
therapeutic interventions that have been proven
to reduce mortality or would be expected to do so.
These interventions include adequate early
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resuscitation with appropriate ﬂuid, inotropes or
vasopressors, ventilation according to the ARDS-
net criteria, utilisation of low-dose steroids in
situations of relative cortisol deﬁciency, insulin
infusion to maintain euglycaemia, early enteral
nutrition and the administration of the anticoagu-
lant and anti-inﬂammatory agent drotrecogin-a
(activated protein C). In addition to the above, the
utilisation of appropriate antibiotics, adminis-
tered at an early stage of therapy, is recognised
to be pivotal in ensuring a positive outcome.
Antibiotic selection
Antibiotic management has become particularly
topical because of the realisation that inappropri-
ate therapy is associated with higher mortality
and that indiscriminate use of broad-spectrum
antibiotics is driving the development of
in-hospital resistance [6–8]. There are currently
more than eight studies, only some of which are
referenced in this paper, demonstrating that
inappropriate initial therapy is associated with a
signiﬁcant increase in mortality, which is not
reversed by changing the antibiotics once the
sensitivity is known [9–12]. One of these studies
demonstrated that in-hospital mortality was
eight-fold greater for patients receiving inappro-
priate therapy within the ﬁrst 24 h (relative risk
1.4 (1.11–1.80) log rank p ¼ 0.0017 vs. those
receiving appropriate therapy) [13]. The likeli-
hood that therapy will be appropriate depends on
the levels of resistance in the unit (for example, if
resistance levels are low, inappropriate therapy
would be unusual). Risk factors for resistance
include having previously received antibiotics,
duration of hospital stay (> 5 days), previous
hospitalisation and mechanical ventilation [14–
16].
As a consequence, although it would be pref-
erable for treatment to be culture-driven, empir-
ical therapy is usually necessary and should be
designed to cover the pathogens most frequently
encountered in each particular unit. Pathogens
vary from unit to unit, from hospital to hospital
and, temporally, within units themselves; and
thus routine surveillance should be performed
frequently and repetitively [12,17,18]. This may
well mean that it is necessary to employ both
Gram-positive and Gram-negative coverage.
Empirical Gram-negative coverage, depending
on unit sensitivities, includes one or more of the
following: cefepime, imipenem, meropenem,
piperacillin–tazobactam, ciproﬂoxacin ⁄ levoﬂoxa-
cin or ertapenem. Very few new effective
‘Gram-negative’ antibiotics are in the pipeline.
Although tigecycline will soon be available and
will be extremely useful against Acinetobacter, it
has no efﬁcacy against Pseudomonas [19]. Com-
pounding this problem of availability is the prob-
lem of ‘collateral damage’, in which overuse of
certain antibiotics, in particular the third-genera-
tion cephalosporins and the ﬂuoroquinolones,
predisposes to selection of resistant organisms
such as those with extended-spectrum, b-lacta-
mases, vancomycin-resistant enterococci and
multidrug-resistant Pseudomonas. Utilisation of
these classes of antibiotics within the unit as
‘workhorse’ antimicrobial agents should be dis-
couraged [20].
Limitation of antibiotic use:
i) Monotherapy
The limitations that exist in relation to availability
of antibiotics necessitate ‘husbandry’ of this
scarce resource by appropriate management of
their use. A reduction of the antibiotic load in the
hospital environment is the major factor likely to
reduce selective pressure. There is, for example, a
conﬂict of interest with regard to the use of
monotherapy or combination therapy. Although,
as has been discussed above, inadequate initial
therapy increases mortality, it is not always
necessary to utilise two agents to cover Gram-
negative infections unless resistance levels are
particularly high in a speciﬁc unit. Even in this
circumstance, continuation with monotherapy
once the sensitivity is known is equally effective
as combination therapy, even for Pseudomonas
infections [21,22].
ii) Duration
As most clinical parameters of sepsis resolve
within the ﬁrst 6 days of therapy, and decreasing
the duration of empirical antibiotic use can
reduce the incidence of hospital-acquired super-
infection, duration should not exceed 7–8 days
[23].
A recent study demonstrated the efﬁcacy of
short-course therapy (8 vs. 15 days) for ventilator-
associated pneumonia (VAP). Although Pseudo-
monas infection was more likely to recur with the
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use of shorter courses, mortality was similar and
there was a signiﬁcant reduction in the emergence
of resistance [24].
iii) De-escalation and discontinuation
Similarly, the practice of routine de-escalation,
once sensitivities are known, is likely to reduce
resistance to the more extended-spectrum antibi-
otics [25]. However, this practice is difﬁcult to
apply to all patients, because a culture is not
always available, resistance levels are high and
physicians are often reluctant to ‘rock the boat’ if
the patient is improving. In a recent study,
de-escalation took place in only approximately
30% of cases, despite the existence of an active
de-escalation policy [26]. Early discontinuation of
antibiotics when a non-infectious aetiology has
been conﬁrmed or where prompt clinical resolu-
tion of infection has also been demonstrated to
be a viable alternative. With use of this regimen,
the duration of antibiotic use was reduced from
8.0 ± 5.6 days to 6.0 ± 4.9 days. Despite this,
occurrence of a secondary episode of VAP, hos-
pital mortality and the duration of intensive care
unit (ICU) stay were similar [27].
iv) Restriction and rotation
Restriction of certain agents has been associated,
in general, with increased infection by organisms
resistant to the replacement antibiotic. The long-
term impact of this practice is unknown. Rahal
et al. restricted use of third-generation cephalo-
sporins to combat an outbreak of infections
caused by extended-spectrum b-lactamase-pro-
ducing Klebsiella. This was associated with a 44%
reduction in infection and colonisation with
extended-spectrum b-lactamase-producing Klebsi-
ella, a 140% increase in the use of imipenem and a
69% increase in the incidence of imipenem-
resistant Pseudomonas aeruginosa throughout the
medical centre [28]. However, a 26% reduction in
third-generation cephalosporin use in another
study was accompanied by a 277.7% increase in
cefepime usage, resulting in improved suscepti-
bility to 3rd generation cephalosporins and infec-
tion-related hospital mortality was signiﬁcantly
reduced: 19% vs. 36.3% (p ¼ 0.014) [29].
Rotation or cycling is possibly also of beneﬁt.
Gruson et al. introduced supervised antibiotic
rotation and restricted the use of ceftazidime
and ciproﬂoxacin. The selection of antibiotics was
based on monthly reviews of pathogens isolated
from the ICU and susceptibility patterns. Gruson
et al. observed a decrease in VAP, primarily
because of a reduction of episodes due to antibi-
otic-resistant Gram-negative bacteria, including
P. aeruginosa, Burkholderia cepacia, Stenotrophomon-
as maltophilia and Acinetobacter baumannii, and
their initial results were sustained over a 5-year
period [17,30]. Not all studies have demonstrated
beneﬁts from rotation, however. A more recent
study by Warren et al. did not demonstrate a
reduction in resistance levels using this practice
[31]. However, the number of resistant isolates
was underestimated at the time of study design
and, as a consequence, the study was underpow-
ered to detect emergence of resistance in the
intervention phase. It is still possible that this
practice may be of value, although resistance
levels make it difﬁcult to ﬁnd at least four
antibiotics which are likely to be effective as
monotherapy in the rotational cycles.
Reduction in infection
The current resistance crisis means that every
effort should be made to reduce the incidence of
infection in the hospital, and the ICU in partic-
ular. Intensive insulin therapy, reduction in the
use of urinary catheters, strictly sterile insertion
of central venous catheters and efforts to reduce
intubation and the duration of ventilation have
all proved to be effective interventions. Simi-
larly, maintenance of semi-recumbent posture
(45), avoidance of nasal intubation and careful
disposal of condensate reduce the incidence of
VAP [32–35]. Reduction in blood transfusions
and, in one prospective randomised control
trial, the use of leukocyte-depleted red blood
cell transfusions have resulted in a reduced
incidence of post-operative infections, and spe-
ciﬁcally, a reduced incidence of pneumonia in
patients undergoing colorectal surgery [36,37].
Enteral nutrition is preferred over parenteral
nutrition, to reduce the risk of complications
related to central venous catheters and to
prevent villous atrophy of the intestinal mucosa,
which may increase the risk of bacterial trans-
location [38].
Effective infection control measures, staff
education, compliance with alcohol-based hand
disinfection practices and isolation to reduce
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cross-infection with multidrug-resistant patho-
gens should be maintained routinely [39,40].
Unfortunately 37% of ICU physicians and
22.3% of nurses do not adhere to preventative
protocols [41,42]. Lack of resources, costs and
fear of adverse effects all play a part in this
failure.
Importantly, awareness of and education
regarding VAP prevention do actually reduce
the incidence of VAP and thereby reduce antibi-
otic usage [43] Stafﬁng in the ICU is another factor
contributing to the rate of sepsis. Some cost
reduction initiatives, such as low nurse ⁄patient
ratios and the utilisation of poorly trained or
untrained staff, are associated with lapses in
infection control [44–48]. In addition, stafﬁng of
units with intensivists, as per ‘Leapfrog’ recom-
mendations, decreases VAP rate [49].
Conclusion
In conclusion, we are faced with a crisis of
potentially devastating proportions. No new anti-
biotics to combat resistant hospital-acquired
infections are likely to be developed in the next
decade, and thus the precious resource that we
currently have must be nurtured and protected as
far as is possible. Resistance cannot be eradicated,
but perhaps we can prolong the lifespan of
currently available antibiotics [50].
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